Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Summit Therapeutics Q4 and year-end 2025 earnings call. All participants will be in listen-only mode until the question and answer session portion of this call. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's website for updates. Please note that today's call is being recorded. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. At this time, I would like to turn the call over to Dave Gancars at Summit Therapeutics, Chief Business and Strategy Officer. You may proceed. Good afternoon, and thank you for joining us. On today's call, we will provide an update on our fourth quarter and year-end 2025 financial results and operational progress. This afternoon's press release is available on our website, www.smmtx.com. Our Form 10-K was also filed today and is available on our website and via the SEC's website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website. Joining me on the call today is Bob Duggan, our Chairman of the Board and Co-Chief Executive Officer. Dr. Matthew Zangane, our President and Co-Chief Executive Officer. Manmeet Soni, our Chief Operating Officer and Chief Financial Officer. And Dr. Alan Yang, Chief of R&D Strategy. I'm Dave Gancars, the Chief Business and Strategy Officer at Summit. Before we get started with the rest of the call, I would like to note that som...